Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences
GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 9th to 11th in Snowbird, UT and the Noble Capital Markets Emerging Growth Virtual Equity Conference being held February 4th to 5th.
紐約州花園城，2026年1月27日（環球新聞社）—— Beyond Air, Inc.（納斯達克股票代碼：XAIR）（「Beyond Air」或「公司」），一家專注於利用一氧化氮的力量來改善患者生活的商業階段醫療設備和生物製藥公司，今天宣佈Steve Lisi，Beyond Air董事長兼首席執行官，將參加於2月9日至11日在猶他州Snowbird舉行的第13屆BTIG醫療技術、數字健康、生命科學與診斷工具會議，以及於2月4日至5日舉行的Noble Capital Markets新興成長虛擬股權會議。
| BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference | ||
| Format: | One-on-one meetings | |
| Conference Dates: | February 9thto 11th | |
| Participant: | Steve Lisi, Chairman & CEO, Beyond Air | |
| Noble Capital Markets Emerging Growth Virtual Equity Conference | ||
| Format: | Corporate presentation and one-on-one meetings | |
| Presentation Date: | Thursday, February 5that 2:00pm ET | |
| Participant: | Steve Lisi, Chairman & CEO, Beyond Air | |
| Live Webcast link: | Attendees interested in viewing the live presentation can register for this event at no cost, here: Virtual Equity Conference Registration. An archive of the webcast will be available at for 90 days following the event | |
| BTIG醫療技術、數字健康、生命科學與診斷工具會議 | ||
| 格式： | 一對一會談 | |
| 會議日期： | 2月9日至11日 | |
| 參會者： | Steve Lisi，董事長兼首席執行官，Beyond Air | |
| Noble Capital Markets新興成長虛擬股權會議 | ||
| 格式： | 公司演講及一對一會談 | |
| 演講日期： | 2月5日星期四東部時間下午2:00 | |
| 參會者： | Steve Lisi，董事長兼首席執行官，Beyond Air | |
| 網絡直播鏈接： | 有興趣觀看現場演示的與會者可以在此免費註冊參加此次活動：虛擬股權會議註冊。活動結束後，網絡直播的存檔將在90天內可供訪問。 | |
If you are interested in requesting a one-on-one meeting at either of the conferences, please contact your respective bank representative to schedule accordingly.
如果您有興趣在任一會議上申請一對一會議，請聯繫您各自的銀行代表進行安排。
About Beyond Air, Inc.
Beyond Air is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval and CE Mark for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria (NTM).
關於Beyond Air公司
Beyond Air是一家商業階段的醫療設備和生物製藥公司，致力於利用內源性和外源性一氧化氮（NO）的力量來改善患有呼吸系統疾病、神經系統疾病和實體瘤的患者的生活。該公司已獲得FDA批准和CE認證，其首個系統LungFit PH用於治療患有低氧性呼吸衰竭的足月和近足月新生兒。Beyond Air目前正在推進其他革命性的LungFit系統進行臨床試驗，以治療嚴重的肺部感染，例如病毒性社區獲得性肺炎（包括COVID-19）和非結核分枝桿菌（NTM）。
Additionally, Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit .
此外，作爲Beyond Air關聯公司的Beyond Cancer, Ltd.正在臨床前環境中使用專有遞送系統研究超高濃度的一氧化氮以針對某些實體瘤。如需更多信息，請訪問 。
CONTACTS:
聯繫方式：
Investor Relations
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
投資者關係
Corey Davis，博士
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
譯文內容由第三人軟體翻譯。
